Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1038 results
June 2015
-
Media ReleaseNovartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watchesNew features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments These apps…
-
Media ReleaseNovartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline Neuropathic pain is a chronic…
-
Media ReleaseNovartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patientsIn the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…
-
Media ReleaseNovartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of actionFarydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
-
Media ReleaseSandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers…
-
Media ReleaseNovartis highlights strong innovation momentum at its second Meet Novartis Management investor dayStrong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
-
Media ReleaseAlcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgeryInnovative AcrySof® IQ PanOptix® trifocal intraocular lens design to improve near to intermediate vision and increase independence from glasses More than three million cataract surgeries…
-
Media ReleaseNovartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CMLPatients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…
-
Media ReleaseNovartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease controlPreplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
-
Media ReleaseNovartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myelomaPanobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an…
-
Media ReleaseNovartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemiaArzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…
-
Media ReleaseNovartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patientsNew analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
Pagination
- ‹ Previous page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- › Next page